An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

Abstract Background A recombinant form of antithrombin (AT), called AT gamma, is being developed as an alternative to AT derived from human plasma. To compare the efficacy and safety of AT gamma to plasma-derived AT (pAT), we conducted a randomized, open-label, multicenter trial in patients with sep...

Full description

Bibliographic Details
Main Authors: Shigeatsu Endo, Ryutaro Shimazaki, the Antithrombin Gamma Study Group
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Journal of Intensive Care
Subjects:
Recombinant form of human AT
AT gamma
DIC
DIC recovery
Survival
JAAM DIC criteria
Online Access:http://link.springer.com/article/10.1186/s40560-018-0339-z

Internet

http://link.springer.com/article/10.1186/s40560-018-0339-z

Similar Items